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Many growth factors are implicated in the pathogenesis
of proliferative diabetic retinopathy. Alteration of growth
factors and their receptors in diabetes has been shown in
both experimental and clinical studies. Sustained hyper-
glycemiaresultingfromlong-standingdiabetesleadstosev-
eral biochemical abnormalities that consequently result in
retinalhypoxia.Retinaloxygenationstateregulatesvarious
growth factors that promote angiogenesis in order to meet
theoxygendemandsofthetissue.However,unregulatedex-
pression of these growth factors and induction of complex
cascades leading to augmentation of other proangiogenic
factors, which may not be regulated by tissue oxygenation,
leads to uncontrolled retinal neovascularization and blind-
ness in diabetic patients.
INTRODUCTION
DiabeticretinopathyisavascularcomplicationofbothtypeI
and type II diabetes. Nearly all people with type I and more
than half with type II diabetes develop complications involv-
ing the retina (Fong et al., 2003). Clinically, diabetic retinopa-
thy can be classiﬁed as background retinopathy (BDR), pre-
proliferative retinopathy (PPDR), and proliferative retinopathy
(PDR) (Alder et al., 1997; Davis, 1992; Hudson, 1996; Neely
et al., 1998). BDR is the earliest stage, which is character-
Received 13 February 2003; accepted 12 April 2003.
The authors acknowledge grant support from Canadian Diabetes
Association, in honor of Margaret Francis, and from Lawson Health
Research Institute.
AddresscorrespondencetoDr.SubrataChakrabarti,Departmentof
Pathology, Dental Sciences Building, University of Western Ontario,
London, Ontario N6A 5C1, Canada. E-mail: schakrab@uwo.ca
izedbycapillarybasementmembranethickening,pericyteloss,
microaneurysms,increasedpermeability,exudatedeposits,and
retinal microinfarcts. Preproliferative retinopathy, on the other
hand, is an advanced stage of retinopathy that subsequently
leads to the proliferative stage. Progression to the proliferative
stage results in neovascularization and accompanying hemor-
rhages.
Retinal changes in diabetes are thought to be initiated by
sustained hyperglycemia leading to biochemical anomalies
and alterations of various vasoactive factors and growth fac-
tors (Brownlee, 2001; Engerman et al., 1985; Diabetes Con-
trol and Complications Trial Research Group, 1993; King and
Brownlee,1996;SheetzandKing,2002).Biochemicalchanges
that are believed to alter the structural and functional prop-
erties of the retina include nonenzymatic glycation (Bierhaus
et al., 1998; Brownlee et al., 1988; Kern and Engerman, 2001;
Vlassara,2001;Vlassara,1997;Takagietal.,1995),augmented
polyol pathway and pseudohypoxia due to redox imbalance
(Costantino et al., 1999; Engerman et al., 1993; Greene et al.,
1987; Ido et al., 1997; Pugliese et al., 1991; Williamson et al.,
1993), oxidative stress (Brownlee, 2001; Pugliese et al., 1991;
Sheetz and King, 2002), and activation of protein kinase C
(PKC)(DerubertisandCraven,1994;Ishiietal.,1996;Ishizuka
et al., 1989; Johannes et al., 1994; Koya and King, 1998;
Lynch et al., 1990; Okumura et al., 1991; Williams et al., 1997;
Xia et al., 1994). In addition, there is also alteration in the ex-
pression of several growth factors, vasoactive factors, and their
respectivereceptors.Earlyinthediseasecourse,thesebiochem-
ical anomalies lead to alteration of retinal blood ﬂow, in part
because of impaired nitric oxide activity and up-regulated en-
dothelin expression (Brownlee, 2001; Sheetz and King, 2002).
With progression of the disease, vascular cells lose intercellu-
lar tight junctions and become susceptible to degeneration, the
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aftermath being increased permeability. Elaboration of growth
factors such as vascular endothelial growth factor (VEGF) and
endothelins,stimulatedbyhyperglycemiaandcellulardegener-
ation,leadtofurtherincreasedpermeabilityandincreasedextra-
cellular matrix (ECM) protein deposition. A schematic outline
of these events and their possible interactions are presented in
Figure 1.
Angiogenesisisacomplexbutnormalprocessundervarious
physiological conditions. However, when unregulated, it may
beaprinciplemechanismoftissuedamageinspeciﬁcpatholog-
ical conditions, as is the case in PDR. Angiogenesis may be the
most devastating outcome of growth factor alterations in PDR.
Retinal neovascularization is believed to be the consequence of
hypoxia due to retinal capillary closure. This idea is supported
by studies that have shown concurrent occurrence of hypoxia
and neovascularization (Patz, 1982; Shimizu et al., 1981). This
hypoxia-inducedstateisbelievedtocausefunctionalalterations
in various cell types, including glial cells, endothelial cells,
retinal pigment epithelial cells, vascular smooth muscle cells,
ﬁbroblasts, and inﬂammatory cells. However, the primary tar-
get of glucose-induced dysfunction is endothelial cells (Chakir
and Plante, 1996; De Vriese et al., 2001; Hink et al., 2001;
King et al., 1994) and they are therefore most susceptible to
proliferating signals.
Numerousgrowthfactorshavebeenimplicatedinthepatho-
genesis of PDR. Growth factor alterations are believed to be
important in both early and late stages of diabetic retinopathy.
Early events in the disease course, dictated in part by growth
factor alterations, include basement membrane thickening, a
hallmark of chronic diabetic complications. Pericyte loss and
endothelial cell damage are two factors that may further aggra-
vate a growth factor–mediated proliferative response, resulting
in increased ECM deposition and basement membrane thick-
ening(WilliamsonandKilo,1983).Inaddition,variousgrowth
factors are involved in later stages of diabetic retinopathy, lead-
ingtoproliferationandmigrationofendothelialcellsandsubse-
quentneovascularization(CaseyandLi,1997;D’Amore,1994;
Grant et al., 1987; Gross et al., 1983; Sholley et al., 1984). Sev-
eral of these growth factors are also believed to participate in
the balance of ECM protein expression and degradation, a phe-
nomenonintegraltoangiogenesis(Hinketal.,2001;Ishiietal.,
1996; Patz, 1982; Shimizu et al., 1981; Williams et al., 1997).
Proteinases called plasminogen activators (PAs) carry out the
conversion of plasminogen to plasmin, which plays an impor-
tantroleintheproteolysisoftheECMproteins.Otherproteases,
matrix metalloproteinases (MMPs), also degrade various ECM
proteins.NaturallyoccurringinhibitorsofPAsandMMPs,such
as plasminogen activator inhibitors (PAIs) and tissue inhibitor
of matrix metalloproteinases (TIMPs) are, in addition to PAs
and MMPs, believed to be regulated by various growth factors
(Casey and Li, 1997; D’Amore, 1994; Grant et al., 1987; Gross
et al., 1983; Sholley et al., 1984).
The involvement of growth factors in PDR is supported by
studies that have shown increased detection in vitreous sam-
ples and whole retinal tissues. Although conﬂicting reports
have been published over the years, it is clear that alteration
in growth factor expression is an important event that may in
part be responsible for the development and progression of dia-
betic retinopathy to the proliferative stage. We will discuss the
pathophysiologicalroleofsomespeciﬁcgrowthfactorsthatare
believed to be involved in PDR.
INSULIN-LIKE GROWTH FACTOR-I (IGF-I)
The IGFs, IGF-I and IGF-II, share considerable sequence
homology with insulin (D’Amore, 1994). These growth fac-
tors are produced by a number of cell types, although liver
seems to be the major contributor. These growth factors act by
bindingtocellsurfacereceptors,IGF-IRandIGF-IIR(LeRoith
and Roberts, 1993). IGF-IR binds IGF-I with higher afﬁnity
than IGF-II and insulin. IGF-IIR, on the other hand, pref-
erentially binds IGF-II. Several circulating proteins, insulin-
like growth factor binding proteins (IGFBPs), are responsible
for the bioavailability and half-life of the IGFs (LeRoith and
Roberts, 1993). The ﬁrst indication as to the role of IGF-I in
diabetic retinopathy came from a study in which hypophysec-
tomy lead to a reduction in the severity of the diabetic eye con-
dition (Poulsen, 1953). A possible role of growth hormone was
promptly proposed following this observation as growth hor-
mone mediates its effects via IGF-I. Consequently, the role of
IGF-I in diabetic complications, including diabetic retinopathy
has been extensively studied. There are contradictory reports
as to the correlation between IGF-I and the clinical stage of
diabetic retinopathy (Agardh et al., 1992; Boulton et al., 1997;
Danis and Bingaman, 1997; Dills et al., 1991; Lee et al., 1994;
Lowe et al., 1995; Meyer-Schwickerath et al., 1993; Pfeiffer
etal.,1997;Wangetal.,1995).Itshouldbenotedthatautocrine
andparacrinetissueproductionofIGF-Imightcontributetothe
inconsistency in correlation studies. In addition, when IGF-I
levels are corrected for age, a signiﬁcant increase in IGF-I lev-
els in diabetic subjects is evident (Boulton et al., 1997). IGF-I
is also increased in vitreous samples from patients with PDR
(Merimee et al., 1983). In support of a possible connection be-
tween IGF-I and diabetic retinopathy, is the observation that
administrationofrecombinantIGF-Iintothevitreouscavityof
animals results in diabetic retinopathy–like pathologic changes
(Thrailkill et al., 1999).
Functionally, IGF-I has been demonstrated to be angio-
genic (King et al., 1985; Nakao-Hayashi et al., 1992; Nicosai
et al., 1994). IGF-I has been shown to cause retinal capillaryGROWTH FACTORS IN PDR 289
FIGURE 1
Schematic illustration of the pathogenesis of proliferative diabetic retinopathy. Chronic hyperglycemia leads to various
biochemical abnormalities that ultimately lead to retinal ischemia and susceptibility to unregulated angiogenesis. Many growth
factors are up-regulated along with their respective receptors. An imbalance between proangiogenic and antiangiogenic factors
leads to new blood vessel formation in the retina. Due to the fragile nature of the newly formed blood vessels and inadequate
cell-cell junctions, the vessels are prone to leakage and hemorrhage. The course of diabetic retinopathy ultimately leads to retinal
and vitreous hemorrhage and retinal detachment.290 Z. ALI KHAN AND S. CHAKRABARTI
endothelial cells to proliferate and migrate (Grant et al., 1987).
Furthermore, implantation of IGF-I pellet in corneas of rabbits
causes neovascularization (Grant et al., 1993). However, it is to
benotedthatthedoseusedinthisstudywassigniﬁcantlyhigher
than that found in retinal and vitreous samples from patients
with PDR. Interestingly, IGF-I is capable of increasing expres-
sion of VEGF in vivo and in vitro (Punglia et al., 1997). IGF-I
can also increase transforming growth factor-β bioavailability
viaincreasedPAactivity(Grantetal.,1990).Thissuggeststhat
IGF-Imightbeimportantindirectingangiogenesisbyitselfand
also by regulating various other growth factors.
PLATELET-DERIVED GROWTH
FACTOR (PDGF)
PDGFsareproducedbyanumberofcellsincludingplatelets,
endothelialcells,vascularsmoothmusclecells,ﬁbroblasts,and
macrophages (Heldin and Westermark, 1999; Raines, 1993).
There are three forms of this growth factor, which are produced
byhomo-andheterodimerizationoftwopolypeptides,PDGFA
andPDGFB.TworeceptorsforPDGFhavebeencloned(Heldin
and Westermark, 1999; Raines, 1993). PDGF AA polypep-
tide binds to α receptors whereas PDGF BB polypeptide and
PDGFheterodimer(PDGFAB)bindstobothαandβ receptors.
Similar to other growth factor receptors, PDGF receptors also
posseses intrinsic tyrosine kinase activity. Vascular endothelial
cells express both PDGF A and B polypeptides along with β
receptors (Bar et al., 1989; Dicorleto and Brown-Pope, 1983;
Raines et al., 1990; Smits et al., 1989). Generally, β receptors
are involved in cell growth, which is the case with endothelial
cells. Activation of β receptors on endothelial cells leads to
transduction of strong mitogenic signals (Battegay et al., 1994;
Kuwabara et al., 1995; Raines et al., 1990).
Both in vivo and in vitro studies indicate that PDGF pos-
sesses an angiogenic property (Marx et al., 1994; Risau et al.,
1992;Satoetal.,1993).PDGFlevelshavebeenshowntobeup-
regulated in vitreous samples from patients with PDR (Cassidy
et al., 1998; Endo et al., 2000; Freyberger et al., 2000). In ad-
dition, PDGF has been shown to augment VEGF expression
in response to hypoxia (Stavri et al., 1995). Whether PDGF
augments or aggravates the effects of angiogenic factors in the
context of PDR, other than VEGF, remains to be determined.
However, in a recent study, it was demonstrated that PDGF BB
causes increased expression of endothelin-1 in bovine retinal
pigment epithelial cells and endothelial cells, which was inhib-
ited by a general PKC inhibitor (Yokota et al., 2003). PDGF is
also believed to be important in the early pathogenetic changes
in the retina. It has been demonstrated that PDGF ablation
in endothelial cells produces morphological changes, such as
microaneurysms and acellular capillaries (Enge et al., 2002),
which are reminiscent of early vascular changes in diabetic
retinopathy.
BASIC FIBROBLAST GROWTH
FACTOR (bFGF)
FGF is a heparin-binding peptide (Esch et al., 1985; Gospo-
darowicz et al., 1986; Sporn and Roberts, 1988). FGF is pro-
duced by a variety of cells, including ﬁbroblasts, macrophages,
and endothelial cells (Enge et al., 2002; Esch et al., 1985;
Gospodarwicz et al., 1986; Schweigerer et al., 1987, 1988;
Sporn and Roberts, 1988; Sternfeld et al., 1989). Two isoforms
of FGFs have been cloned, acidic FGF (aFGF) and basic FGF
(bFGF).Thesetwoisoformsshare53%sequencehomologyand
possessmitogenicpropertiestowardﬁbroblastsandendothelial
cells (De Juan et al., 1990; Schweigerer et al., 1987). bFGF is
found in nearly all tissues, whereas, aFGF is mainly present
in neural tissues. Generally, bFGF is a protein localized to the
ECM, bound to heparin, which protects it from degradation
(Bashkin et al., 1989; Prestrelski et al., 1992; Saksela et al.,
1988; Sommer and Rifkin, 1989). A lack of secretory signal
on bFGF suggests that it might be introduced to the ECM by
tissue damage or an exocytotic process (Gajdusek and Carbon,
1989; Muthukrishnan et al., 1991). Expression of FGF and its
receptor in the retina prompted researchers to study the role of
FGF in PDR in great detail (Baird et al., 1985; Hanneken et al.,
1991; Khaliq et al., 1995).
In vivo angiogenesis assays have shown that bFGF is a very
potent angiogenic factor (Glaser et al., 1980a, 1980b; Wong
et al., 2001). It is also increased in vitreous samples from pa-
tients with PDR (Sivalingam et al., 1990). Exogenous adminis-
tration of bFGF has been shown to induce endothelial prolifer-
ation and VEGF expression (Stavri et al., 1995). Both of these
effects suggest important roles in retinal neovascularization.
However, there still remains quite a controversy as to the exact
in vivo role played by these factors. In vivo and in vitro stud-
ies have demonstrated increased bFGF expression in various
systems. However, bFGF immunostaining has only been local-
ized to mature nonproliferating blood vessel cells (Hanneken
et al., 1991). In addition, hyperglycemia has been shown to
cause glycosylation of bFGF (Giardino et al., 1994), which
reduces its mitogenic activity. It is plausible that bFGF is in-
volvedinincreasedexpressionofothersecretedangiogenicfac-
tors, such as VEGF, which promote proliferation of endothelial
cells.
TRANSFORMING GROWTH
FACTOR-β (TGF-β)
TGF-β isaveryimportantcytokineinﬁbroticdiseasesofthe
liver,kidney,andlungs.TGF-β isamemberofalargefamilyofGROWTH FACTORS IN PDR 291
regulatory proteins that include activin, inhibin, and bone mor-
phogenic protein (Barnard et al., 1990; Ruscetti et al., 1998).
MammalsexpressthreeTGF-β isoforms(β1,β2,andβ3),which
are encoded by separate genes. TGF-β shows widespread tis-
sue distribution and biological actions. In diabetic retinopa-
thy, the role of TGF-β seems to be complex. TGF-β has been
shown to be up-regulated by high glucose levels in human reti-
nal endothelial cells (Pascal et al., 1999). In addition, TGF-β2
levels were found to be increased in vitreous samples from
patients with PDR (Hirase et al., 1998). Although, TGF-β ex-
ihibits antiproliferative activity in vitro, it is implicated in a
positive regulation of angiogenesis in vivo (Battegay, 1995;
Beck and D’Amore, 1997; Bussolino et al., 1997; Folkman
and Klagsburn, 1987; Merwin et al., 1991; Muller et al., 1987;
Roberts et al., 1986; Yang and Moses, 1990). This discrep-
ancy is the least understood aspect of TGF-β action. Several
theories have been proposed to reconcile these contradictory
reports. The most attractive being the chemoattractant theory.
According to this postulate, TGF-β acts as a chemoattractant
forvariouscelltypes,includingﬁbroblastsandmonocytes,both
of which are capable of producing angiogenic factors such as
VEGF, PDGF, and tumor necrosis factor (TNF)-α (Phillips
et al., 1993; Sakamoto et al., 2000). Furthermore, some in
vitro evidence exists that implicates expression of TNF-α in
TGF-β–mediated angiogenesis (Iruela-Arispe and Sage, 1993;
Vinals and Pouyssegur, 2001). This theory suggests an indirect
role of TGF-β in angiogenesis mediated either by bystander
cells or by the induction of angiogenic factors. Further sup-
port for its involvement in PDR is the observation that TGF-β
modulates VEGF expression in endothelial cells (Pertovaara
et al., 1994). Endothelial cell permeability is another aspect
that is in part regulated by TGF-β (Behzadian et al., 2001). It
has been demonstrated that TGF-β regulates retinal endothe-
lial permeability by modulating proteases which degrade ECM
proteins.
Interestingly, various other growth factors that are altered in
chronic diabetic complications (VEGF, IGF-I, bFGF) increase
theactivityofPAs,whichconvertplasminogentoplasmin.Plas-
min is involved in producing a conformational change in the
latent TGF-β–binding protein, leading to release of TGF-β in
bioactive form. Increased TGF-β, in turn, can modulate ECM
protein synthesis and degradation, a balance that is altered in
diabetic retinopathy.
VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF)
VEGFs are a family of growth factors with ﬁve isoforms
that are produced from a single gene by alternative splicing
(Robinson and Stringer, 2001). These growth factors are also
produced by a variety of cells, including macrophages, vascu-
lar smooth muscle cells, vascular endothelial cells, and retinal
pigment epithelial cells. These growth factors act on VEGF
receptors (ﬂt-1 and ﬂk-1), which are mainly localized on vas-
cular endothelial cells and probably to some extent on vascular
smoothmusclecells(DeVriesetal.,1992;HewettandMurray,
1996; Terman et al., 1992). VEGF has been shown to be mi-
togenic for endothelial cells and its expression is increased in
various animal models prior to neovascularization (Clermont
et al., 1997; Favard et al., 1996; Gerhardinger et al., 1998;
Grunwald, 1998; Lu and Adamis, 2002; Miller et al., 1997;
Noma et al., 2002; Ohno-Matsui et al., 2002; Pe’er et al., 1996;
Tanaka et al., 1997). In addition, it is up-regulated in hypoxic
conditions and is also modulated by various other growth fac-
tors as mentioned earlier (Donahue et al., 1996; Marsh et al.,
2000; Oh et al., 1999). It has been shown to be up-regulated
in vitreous samples of patients with active PDR (Aiello et al.,
1994; Endo et al., 2001; Funatsu et al., 2001; Mitamura et al.,
2002; Ogata et al., 2002; Shinoda et al., 1999; Simo et al.,
2002). This suggests that VEGF might be the perfect candi-
date to carry out signals for retinal neovascularization. A PKC-
dependent pathway has been thought to mediate VEGF acti-
vation (Zhou et al., 2002). On the other hand, the mechanism
by which VEGF carries out its action also seems to involve
PKC activation. VEGF binding to the receptor results in in-
creased phosphatidylinositol 3-kinase (PI3 kinase) activity and
phospholipase-Cγ (PLCγ)activation(Aielloetal.,1997;Gliki
etal.,2002;Mathewsetal.,1997;Seymouretal.,1996;Teicher
et al., 2002; Wellner et al., 1999; Zhou et al., 2002). The subse-
quent increase in diacylglycerol (DAG) results in activation of
PKCisoformsα andβ.IthasbeenshownthatinhibitionofPKC
prevents VEGF-mediated increased permeability and prolifer-
ation of endothelial cells (Aiello et al., 1997; Gliki et al., 2002;
Teicher et al., 2002; Wellner et al., 1999). Furthermore, down-
stream effector molecules of VEGF receptor–mediated signal-
ing also include guanine 5 -triphosphate (GTP)ase-activating
protein, in addition to PKC and PI3 kinase (Qi and Claesson-
Welsh, 2001; Suzuma et al., 2000; Takahashi and Shibuya,
1997).
In animal models, chimeric VEGF receptor proteins, which
sequester VEGF and prevent it from binding to the receptors
on cell surfaces, can suppress neovascularization in almost all
animals studied (Aiello et al., 1995; Adamis et al., 1996; Ozaki
et al., 2000). Similar results have been obtained in experiments
utilizing antisense oligonucleotides against VEGF, which lead
to in decreased VEGF production (Robinson et al., 1996). The
useofantisenseoligonucleotidesresultedinsuppressionofneo-
vascularization in almost 75% of animals studied. These ﬁnd-
ings certainly provide evidence of an integral role of VEGF in
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ENDOTHELINS (ETs)
Endothelinsarepotentvasoactivepeptidesthatregulatevas-
cular tone by their action on vascular endothelial and smooth
muscle cells (Levin, 1995; Rubanyi and Polokof, 1994). The
ET family is comprised of three isoforms, ET-1, ET-2, and
ET-3 (Inoue et al., 1989; Levin, 1995; Rubanyi and Polokof,
1994). These peptides are produced by a number of tissues.
The major source of ET-1, the most potent vasoconstrictor, is
vascular endothelium (Yanagisawa et al., 1988). Regulation of
ETs is achieved in a transcription-dependent manner (Levin,
1995; Rubanyi and Polokof, 1994). These vasoactive peptides
interactwithspeciﬁccellsurfacereceptors,ETA,ET B,andETC
(Sakurai et al., 1992; Sumner et al., 1992). Only ETA and ETB
receptortypesarepresentinmammals.Thesereceptorsarecou-
pled to PLC through G proteins. ETA receptors are localized
primarily on vascular smooth muscle cells and are involved in
vasoconstriction (Sakurai et al., 1992; Sumner et al., 1992).
Activation of ETA receptors results in calcium inﬂux via PLC-
mediated DAG and inositol trisphosphate production. ETB re-
ceptorsareinvolvedingenerationofnitricoxidebyendothelial
cells and thus regulate vasodilation.
In addition to a number of inducing factors, tissue hypoxia
and ischemia cause up-regulation of ETs (Blauw et al., 1995;
Karmazyn, 1996). Alteration of ETs has been demonstrated
in both type I and type II diabetes (Bertello et al., 1994; De
Mattia et al., 1998; Donatelli et al., 1994; Haak et al., 1992;
Kamoi et al., 1994; Kawamura et al., 1992; Laurenti et al.,
1997; Letizia et al., 1997; Morise et al., 1995; Takahashi et al.,
1990). Although, a number of studies can be cited that provide
contradictory reports of plasma ET levels in diabetic patients,
it should be noted that these peptides act in both an autocrine
andparacrinefashion.Thereforeplasmalevelsmaynotprovide
an adequate assessment of their biological activity in regards
to the retina (Levin, 1995; Rubanyi and Polokof, 1994). In a
recentstudy,vitreousET-1levelswerefoundtobesigniﬁcantly
elevated in patients with PDR as compared to patients with
nondiabetes associated ocular conditions (Oku et al., 2001).
ETsexhibitmitogenicpropertyonvascularendothelialcells
andmaybeinvolvedindiabetes-inducedretinalneovasculariza-
tion(BekandMcMillen,2000;BrennanandZaki,2000;Chollet
etal.,1993;Morbidellietal.,1995;Salanietal.,2000).Themi-
togenic property was demonstrated in the early 1990s by DNA
synthesis assays. Administration of ET-1 was shown to induce
DNA synthesis in brain capillary endothelial cells (Vigne et al.,
1990). In addition, it has been demonstrated that selective ETB
receptor antagonist can prevent endothelial cell proliferation
and migration, two fundamental steps in the process of angio-
genesis.InfurthersupportoftheroleofETsinthedevelopment
andprogressionofPDRisthestudyfromourlaboratorythathas
demonstrated that ETs are involved in hyperglycemia-induced
increasedpermeability(Chenetal.,2000).Thedownstreamef-
fector molecule regulating ET-mediated mitogenic effects and
increasedpermeabilityseemstobePKCactivation(Chenetal.,
2000;Stanimirovicetal.,1994).Thissuggestsapossibleroleof
these vasoactive factors in mediating hyperglycemia-induced
retinal structural and functional changes associated with
PDR.
PIGMENT EPITHELIUM-DERIVED
FACTOR (PEDF)
Recent advances in diabetic retinopathy research have re-
framedourthinkinginregardstotheroleofgrowthfactorspro-
moting angiogenesis. Initially, retinal neovascularization was
thought to be the result of augmented growth factor expression,
which promotes new blood vessel growth. It is now being ac-
cepted that pathologic angiogenesis in the eye is the result of
not only increased vessel growth-stimulating factors but also
decreased antiangiogenic factors. PEDF is such an antiangio-
genic factor, which is believed to carry out its activity by in-
hibiting proliferation of endothelial cells (Dawson et al., 1999;
Hutchings et al., 2002). PEDF has been shown to be present in
the vitreous humor with high antiangiogenic activity, keeping
this ocular portion avascular (Alberdi et al., 1999; Singh et al.,
1998; Wu et al., 1995). Removal of PEDF from vitreous results
in invasion of numerous blood vessels. In addition, induction
of corneal wounds does not normally induce angiogenesis but
does develop neovascular structure when facilitated with anti-
bodiesagainstPEDF(Dawsonetal.,1999).Themechanismby
which PEDF carries out its antiangiogenic activity is still not
clear. However, a receptor has been isolated from retinoblas-
toma cells and also retinal neural cells (Alberdi et al., 1999;
Becerra, 1997). Binding of PEDF to endothelial cells with high
afﬁnityalsosuggeststhepresenceofareceptor,possiblysimilar
to the one isolated from neural cells, on endothelial cells.
TheroleplayedbyPEDFhasnotbeenfullyelucidatedinthe
context of retinal neovascularization. However, it has been re-
cently shown that there is a negative correlation between PEDF
levels and the degree of ischemia-induced neovasularization in
rats (Gao et al., 2001). Low levels of PEDF have also been
associated with angiogenic ocular diseases in humans (Ogata
et al., 2001; Spranger et al., 2001). Furthermore, the antian-
giogenic activity that is believed to be suppressed in retinal
neovascularization can be recovered by administration of re-
combinant PEDF as determined by prevention of retinopathy
(Duh et al., 2002; Mori et al., 2001; Stellmach et al., 2001).
These observations suggest that an imbalance in angiogenic
and antiangiogenic factors, produced by suppressed PEDF and
augmented proangiogenic factors such as VEGF, promote new
blood vessel formation in the retina in PDR.GROWTH FACTORS IN PDR 293
OTHER FACTORS
Apart from the growth factors that we have described so far,
a number of potent factors, which by their angiogenic or other
activities, are involved in diabetic retinopathy. We will brieﬂy
describe our current knowledge in regards to the involvement
of such factors in PDR.
Nerve Growth Factor (NGF)
NGF belongs to the neurotrophin family of polypeptides
that play important roles in survival of neurons in both cen-
tralandperipheralnervoussystem(GreeneandShooter,1980).
Recent studies have indicated that NGF and NGF-mediated
signaling might be important in other biological functions,
including wound healing and inﬂammation (Lawman et al.,
1985; Matsuda et al., 1998). NGF has also been demonstrated
to promote proliferation of microvascular endothelial cells
(Raychaudhuri et al., 2001). This suggests that NGF alteration
might play an important role in the progression of diabetic
retinopathy. Although no difference has been observed in NGF
and NGF receptor immunoreactivity between normal and di-
abetic retina in spontaneously diabetic BB rats (Chakrabarti
et al., 1990), the idea cannot be excluded that some alteration
of NGF takes place in the retina of diabetic subjects. A more
recent study has demonstrated increased serum levels of NGF
in patients with type I diabetes compared to age-matched con-
trolsubjectsandtypeIIpatients(Azaretal.,1999).Inaddition,
several other growth factors that are altered in long-standing
diabetes, such as b-FGF and epidermal growth factor (EGF),
can induce the expression of NGF by ﬁbroblasts and possibly
other cells (Hattori et al., 1993).
Hepatocyte Growth Factor (HGF)
HGF was initially isolated from serum of hepatectomized
rats (Nakamura et al., 1984). This growth factor is produced by
many mesenchymal cells including ﬁbroblasts and endothelial
cells. HGF has been shown to promote endothelial growth and
migrationandtheformationofbloodvesselsinvivo(Bussolino
et al., 1992; Cai et al., 2000; Grant et al., 1993). Only recently,
havealterationsinthevitreouslevelsofHGFbeendemonstrated
in patients with diabetes-induced retinopathy (Nishimura et al.,
1999, 2000). The levels of HGF in vitreous samples parallel
the severity of PDR as determined by vitreous hemorrhage,
ﬁbrovascular proliferation, and tractional retinal detachment.
In addition, the levels of HGF found in this study were in the
rangethathaspreviouslybeenshowntoinducegrowthandpro-
liferation of cultured endothelial cells (Nakamura et al., 1996).
Although HGF is not as aggresively studied as other factors, its
contributions to the development of PDR should not be ruled
out.
Epidermal Growth Factor (EGF)
EGFisahighlymitogenicpolypeptideproducedbyavariety
of cell types (Carpenter, 1985; Lui and Grandis, 2002). A num-
berofstudieshaveconcludedthatEGFismitogenicforcorneal
endothelial cells and is involved in corneal neovascularization
(Nezu et al., 1992; Woost et al., 1992). However, the involve-
ment of EGF and its possible role in regulating retinal angio-
genesis is less characterized compared to this function by other
growth factors. One recent study has shown increased EGF and
EGF receptor immunoreactivity in retinal samples from sub-
jects with PDR (Patel et al., 1994). Although EGF possesses
limitedangiogenicactivityascomparedtoFGF,itishighlymi-
togenic for human retinal pigment epithelial cells and may act
synergistically with FGF (Leschey et al., 1990). This suggests
that EGF signaling might be involved in preretinal membrane
formation. This ﬁnding, along with localization of EGF in pre-
retinal membranes of patients with PDR (Fredj-Reygrobellet
et al., 1991; Patel et al., 1994), points to the involvement of
EGF in the progression of diabetic retinopathy.
Tumor Necrosis Factor-α (TNF-α)
TNF-α is a proinﬂammatory cytokine primarily produced
by phagocytes (Pober and Cotran, 1990). The principle target
of TNF-α is vascular endothelium (Madge and Pober, 2001;
Pober, 1998). The mechanistic basis of TNF-α–mediated en-
dothelial activation is not completely understood. However,
accumulating evidence suggests that TNF-α may mediate al-
teration of vasoregulation and leukocyte adhesion, leading to
endothelial dysfunction. In addition, it is well documented that
TNF-α increases endothelial permeability (Friedl et al., 2002;
Mark and Miller, 1999), an activity important in cell invasion
and migration during angiogenesis. Vitreous and serum from
diabeticsubjectswithPDRdoshowanelevatedlevelofTNF-α
(Doganayetal.,2002;Sprangeretal.,1995;Yuukietal.,2001).
In addition, in vitro studies have demonstrated a potential role
of TNF-α in TGF-β–induced angiogenesis (Iruela-Arispe and
Sage,1993;VinalsandPouyssegur,2001).Thestageofdiabetic
retinopathy at which TNF-α might play a role is still obscure.
However, mere elevation of this proinﬂammatory cytokine in
PDR suggests an association that might be worth pursuing.
CONCLUDING REMARKS
PDRisaverycomplexconditionthatresultsfromalteredex-
pressionofvariousgrowthfactorsandvasoactivefactors.Inthe
retina,hyperglycemiacausesseveralmetabolicdefects,includ-
ing oxidative stress, nonenzymatic glycation, and formation of
advancedglycationend(AGE)products,sorbitol/myo-inositol–
mediated changes, and redox potential alteration. These events
set the background for pericyte loss, basement membrane294 Z. ALI KHAN AND S. CHAKRABARTI
thickening, microaneurysms, acellular capillaries, nonperfu-
sion, ischemia and, therefore, susceptibility towards mitogenic
stimuli. The increase in angiogenic factors or inducers of these
factorsresultsinapropagatingcomplexthatinterplaysbetween
different pathways, resulting in nonregulated angiogenesis. In
addition, hyperinsulinemia due to insulin resistance may also
inﬂuencegrowthfactoralteration.Itistobenotedthatanoblig-
atory role of a particular growth factor in the development and
progressionofdiabeticretinopathyiscontroversial.Ourcurrent
knowledge suggests that a very heterogenous pattern of growth
factor expression, with cross-talks between different pathways
resulting in ocular neovascularization.
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